Psych Congress 2016 Coverage

Psych Congress 2016

Asenapine Appears Effective Even in Advanced Pediatric Bipolar Disorder Progression

By October 23, 2016

Authors of a post-hoc analysis reported that asenapine is effective in the management of pediatric bipolar disorder regardless of the number of prior manic or mixed episodes.

Psych Congress 2016

Early Improvement With Vilazodone Might Predict Response, Remission in GAD

By October 23, 2016

Sufficient dosing and treatment duration might be needed to assess vilazodone's effectivness for management of symptoms among patients with GAD, concluded authors of a pooled analysis of data from three phase 3 clinical trials.

Psych Congress 2016

Oral to Injectable Tx Switch in Patients With Schizophrenia: An Analysis

By October 23, 2016

Study authors presented that most outpatients who started on aripiprazole lauroxil 882mg every 4 weeks remained for the entire year with completion rates ranging between 73.2% (oral aripiprazole) to 52.6% (oral olanzapine).

Psych Congress 2016

Paliperidone Palmitate vs. Oral Atypical Antipsychotics: Hospitalization, ER Visits Compared

By October 23, 2016

Among members of Humana's Medicare Advantage and Prescription Drug plan who have schizophrenia, paliperidone palmitate (PP) was associated with fewer hospitalizations and ER visits than oral atypical antipsychotics (OAAs), and the resulting healthcare system savings offset half of the cost difference between PP and OAAs.

Psych Congress 2016

Patient Assistance Program Might Help Boost Adherence to Antipsychotic LAIs

By October 23, 2016

Patient assistance programs might improve patient adherence with prescribed long-acting atypical antipsychotic injectables among people with schizophrenia, according to findings from a retrospective cohort study.

Psych Congress 2016

High-Dose Baclofen and Mania: What's the Link?

By October 23, 2016

Cases of baclofen-indued mania were seen in psychiatric patients receiving the drug for the mangement of tardive dyskinesia and alcohol dependence.

Psych Congress 2016

Does Adjunct Lurasidone to Lithium or Valproate Improve Bipolar I Disorder?

By October 23, 2016

Up to 20 weeks of treatment with lurasidone adjunctive to lithium or valproate in patients with bipolar I disorder resulted in a "clinically significant mean improvement in depression and mania scores" during the open-label stabilization phase of a randomized study.

Psych Congress 2016

Levomilnacipran ER Improves Functional Impairment, Cognition/Attention in MDD

By October 23, 2016

Levomilnacipran extended-release (ER) significantly improved overall symptoms of depression in patients with major depressive disorder (MDD) and cognitive difficulties.

Psych Congress 2016

Sertraline Overdose Leads to Case of SSRI-Induced Pancreatitis

By October 23, 2016

Does an overdose of a selective serotonin reuptake inhibitor (SSRI) increase risk of occurrence of pancreatitis?

Psych Congress 2016

Lurasidone Has Larger Effect on Schizophrenia Patients With Prominent Positive Symptoms

By October 23, 2016

Lurasidone was associated with medium to large treatment effect sizes in adult patients with schizophrenia who presented with prominent positive symptoms.